AUD2.64
0.38% today
Australia, Dec 30, 06:10 am CET
ISIN
AU000000SIG5
Symbol
SIG
Sector
Industry

Sigma Pharmaceuticals Target price 2024 - Analyst rating & recommendation

Sigma Pharmaceuticals Classifications & Recommendation:

Buy
25%
Hold
25%
Sell
50%

Sigma Pharmaceuticals Price Target

Target Price AUD1.97
Price AUD2.64
Deviation
Number of Estimates 7
7 Analysts have issued a price target Sigma Pharmaceuticals 2025 . The average Sigma Pharmaceuticals target price is AUD1.97. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 2 Analysts recommend Sigma Pharmaceuticals to buy, 2 to hold and 4 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Sigma Pharmaceuticals stock has an average upside potential 2025 of . Most analysts recommend the Sigma Pharmaceuticals stock at Sale.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Jan '24 2025
Estimates
Revenue Billion AUD 3.32 4.61
9.24% 38.88%
EBITDA Margin -1.31% 1.71%
24.57% 230.20%
Net Margin 0.00% 0.92%

7 Analysts have issued a sales forecast Sigma Pharmaceuticals 2025 . The average Sigma Pharmaceuticals sales estimate is

AUD4.6b
Unlock
. This is
32.55% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
AUD4.7b 35.94%
Unlock
, the lowest is
AUD4.5b 30.15%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 AUD3.3b 9.24%
2025
AUD4.6b 38.88%
Unlock
2026
AUD6.0b 29.34%
Unlock
2027
AUD6.3b 4.94%
Unlock
2028
AUD7.2b 14.38%
Unlock
2029
AUD6.5b 9.82%
Unlock

7 Analysts have issued an Sigma Pharmaceuticals EBITDA forecast 2025. The average Sigma Pharmaceuticals EBITDA estimate is

AUD78.7m
Unlock
. This is
267.03% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
AUD86.5m 283.48%
Unlock
, the lowest is
AUD59.3m 225.80%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 AUD-43.6m 13.06%
2025
AUD78.7m 280.47%
Unlock
2026
AUD977m 1,140.31%
Unlock
2027
AUD1.1b 16.62%
Unlock
2028
AUD1.5b 29.01%
Unlock
2029
AUD188m 87.21%
Unlock

EBITDA Margin

2024 -1.31% 24.57%
2025
1.71% 230.20%
Unlock
2026
16.37% 857.31%
Unlock
2027
18.19% 11.12%
Unlock
2028
20.51% 12.75%
Unlock
2029
2.91% 85.81%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Jan '24 2025
Estimates
Earnings Per Share AUD 0.00 0.03
P/E 97.78
EV/Sales 0.88

Based on analysts' sales estimates for 2025, the Sigma Pharmaceuticals stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.17 134.00%
2025
0.88 24.60%
Unlock
2026
0.68 22.68%
Unlock
2027
0.65 4.71%
Unlock
2028
0.57 12.57%
Unlock
2029
0.63 10.87%
Unlock

P/S ratio

Current 1.20 173.82%
2025
0.90 24.55%
Unlock
2026
0.70 22.68%
Unlock
2027
0.67 4.71%
Unlock
2028
0.58 12.57%
Unlock
2029
0.64 10.89%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today